During the corresponding time, Vivos Inc recorded a revenue increase by 34.84 % year on year, sequentially revenue grew by 45.72 %. While revenue at the Vivos Inc's corporate clients
Vivos Inc's Comment on Sales, Marketing and Customers
The Company markets its Precision Radionuclide Therapy™ products, RadioGel® for human use and IsoPet® for veterinary use. Veterinary customers include certified veterinary clinics, university veterinary hospitals, specialty animal oncology centers, and private practices treating small animals, equine patients, and exotic species. As of December 31, 2025, 17 certified regional clinics are operational, including academic institutions such as the University of Florida (small and large animal hospitals), Johns Hopkins University Veterinary Clinical Trials Network, University of Missouri, University of Wisconsin, University of Illinois, and private facilities including Vista Veterinary Hospital, NorthStar VETS, and Sun City Veterinary Surgical Center. These clinics provide minimally invasive, targeted treatment options for solid tumors in pets. For human applications, potential customers include hospitals, oncology centers, interventional radiologists, and medical professionals treating non-resectable solid tumors. The Company focuses on direct sales to certified veterinary clinics and seeks partnerships or institutional adoption in human markets, supported by planned manufacturing diversification in 2026. Growth in awareness and demand is driven by clinic expansions, publications, marketing efforts, and real-world veterinary data demonstrating safety and efficacy.
Vivos Inc’s Comment on Sales, Marketing and Customers
The Company markets its Precision Radionuclide Therapy™ products, RadioGel® for human use and IsoPet® for veterinary use. Veterinary customers include certified veterinary clinics, university veterinary hospitals, specialty animal oncology centers, and private practices treating small animals, equine patients, and exotic species. As of December 31, 2025, 17 certified regional clinics are operational, including academic institutions such as the University of Florida (small and large animal hospitals), Johns Hopkins University Veterinary Clinical Trials Network, University of Missouri, University of Wisconsin, University of Illinois, and private facilities including Vista Veterinary Hospital, NorthStar VETS, and Sun City Veterinary Surgical Center. These clinics provide minimally invasive, targeted treatment options for solid tumors in pets. For human applications, potential customers include hospitals, oncology centers, interventional radiologists, and medical professionals treating non-resectable solid tumors. The Company focuses on direct sales to certified veterinary clinics and seeks partnerships or institutional adoption in human markets, supported by planned manufacturing diversification in 2026. Growth in awareness and demand is driven by clinic expansions, publications, marketing efforts, and real-world veterinary data demonstrating safety and efficacy.
Sources:
Vivos Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Vivos Inc’s corporate clients.
For your research, we’ve provided 9 tables on Vivos Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
197.17 %